Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Docetaxel
100%
Androgens
100%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
100%
Overall Survival
100%
Androstenedione
100%
Testosterone
80%
Dehydroepiandrosterone
80%
Multivariable
40%
Hazard Ratio
40%
Mortality Hazard
40%
Risk of Death
40%
Clinical Outcomes
40%
95% Confidence Interval
40%
Androgen Levels
40%
Placebo
20%
Prednisone
20%
Bevacizumab
20%
Chemotherapy
20%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
20%
Prognostic Value
20%
Chemotherapy-naïve
20%
Docetaxel Chemotherapy
20%
Androgen Receptor Antagonist
20%
Improved Survival
20%
Univariate Analysis
20%
Median Overall Survival
20%
Ketoconazole
20%
Median Value
20%
Serum Assay
20%
Serum Androgens
20%
Tandem Liquid Chromatography
20%
PSA Decline
20%
Medicine and Dentistry
Castration Resistant Prostate Cancer
100%
Overall Survival
100%
Androgen
100%
Docetaxel
100%
Androstenedione
100%
Prasterone
80%
Testosterone
80%
Chemotherapy
60%
Hazard Ratio
40%
Univariate Analysis
20%
Ketoconazole
20%
Liquid Chromatography-Mass Spectrometry
20%
Androgen Therapy
20%
Androgen Synthesis
20%
Placebo
20%
Prednisone
20%
Bevacizumab
20%
Pharmacology, Toxicology and Pharmaceutical Science
Docetaxel
100%
Castration Resistant Prostate Cancer
100%
Overall Survival
100%
Androgen
100%
Androstenedione
83%
Prasterone
66%
Testosterone
66%
Chemotherapy Regimens
50%
Placebo
16%
Bevacizumab
16%
Ketoconazole
16%
Prednisone
16%
Neuroscience
Androgen
100%
Docetaxel
100%
Androstenedione
83%
Dehydroepiandrosterone
66%
Testosterone
66%
Prostate
66%
Chemotherapy
50%
Prednisone
16%
Bevacizumab
16%
Placebo
16%
Liquid Chromatography-Mass Spectrometry
16%
Ketoconazole
16%